SEC I	Form 4
-------	--------

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
an Operation (OO/h) of the discussion of Operations (Act of 10.10)

			or Section So(n) of the investment Company Act of 1940	
1. Name and Address of Reporting Person [*] Sofinnova Capital VII FCPR			2. Issuer Name and Ticker or Trading Symbol Shockwave Medical, Inc. [SWAV]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner
	(First) (Middle) CKWAVE MEDICAL, INC. SY ROSS DRIVE		3. Date of Earliest Transaction (Month/Day/Year) 08/17/2020	Officer (give title Other (specify below) below)
(Street) SANTA CLARA	СА	95054	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	08/17/2020		S		61,823	D	\$ 55.04 ⁽²⁾	2,218,006	D ⁽¹⁾	
Common Stock	08/18/2020		S		133,922	D	\$55.08 ⁽³⁾	2,084,084	D ⁽¹⁾	
Common Stock	08/19/2020		S		18,720	D	\$55.37(4)	2,065,364	D ⁽¹⁾	
Common Stock	08/19/2020		S		40,720	D	\$56.79 ⁽⁵⁾	2,024,644	D ⁽¹⁾	
Common Stock	08/19/2020		S		30,438	D	\$57.08(6)	1,994,206	D ⁽¹⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv	r osed) r. 3, 4		7. Titl Amou Secur Unde Deriv Secur 3 and	int of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Shares held by the reporting person are also reported on Form 4 by Antoine Papiernik, one of the managing partners of Sofinnova Partners SAS, a French corporation and the management company of the reporting person. Mr. Papiernik disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.

2. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$55.00 to \$55.37. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

3. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$55.00 to \$55.40. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

4. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$55.00 to \$55.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

5. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$56.00 to \$56.9989. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

6. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$57.00 to \$57.49. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Remarks:

All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Prior filings by the reporting person reflected clerical errors with respect to the reporting person's holdings of the issuer's common stock. The reporting person's holdings of the issuer's common stock reported here reflect a reduction by 275,436 shares to correct these errors.

 /s/ Trinh Phung, as attorneyin-fact for Sofinnova Capital
 08/19/2020

 VII FCPR
 ** Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.